secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2024-09-09T23:59:59+00:00
Accession:  0001171843-24-005116
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences appoints Rick Barry as CEO; Claude Nicaise becomes Chairman
----------------------------------------------------------------------------

- Richard Barry named CEO effective September 6, 2024; previously Executive Chairman and director since June 2021.
- Board separates CEO and Chairman roles; Claude Nicaise, M.D. appointed Chairman.
- Dr. Nicaise served as director since Dec 2023; held regulatory roles at Alexion and Bristol-Myers Squibb.
- First Phase 3 trial of simufilam (n=804) topline expected by end of 2024; second Phase 3 (n=1,125) by mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184324005116/0001171843-24-005116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184324005116/f8k_090924.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-005116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer